SAN FRANCISCO, Jan. 19, 2016 (GLOBE NEWSWIRE) -- CollabRx, Inc., a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced Adrienne Craig-Kennard will serve as Vice President of Global Business Development and Strategic Alliances.
Craig-Kennard, an expert in international business development with more than 15 years experience in the pharmaceutical, biotechnology, and bioinformatics industries, will lead development and strategy for CollabRx. She has acted in research and product development roles in addition to business development and COO positions in her previous work.
"Adrienne has a brilliant track record as an executive in our industry," said Thomas Mika, CEO of CollabRx. "Her ability to work and think as a scientist as well as a businesswoman has led to global success and we could not be more thrilled to have her join our team."
"CollabRx's ability to deliver expert solutions in precision oncology is paramount in today's market where physicians, laboratories, payers and providers strive to achieve standardized, evidence-based care and superior clinical outcomes," said Adrienne Craig-Kennard. 'My background, coupled with the opportunity to become an integral part in the advancement of oncology care are an ideal fit."
Most recently Craig Kennard was Vice President of Global Clinical Informatics Sales for Strand Life Sciences where she led global sales of software as well as services for translational research and next generation sequencing-based clinical diagnostics.
Craig-Kennard received her Bachelor of Science in Chemistry from the University of California, Berkeley and an M.B.A. from the Grenoble Graduate School of Business in France.
About CollabRx, Inc.
CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About Rennova Health, Inc.
Rennova Health (Nasdaq:RNVA) owns and operates five diagnostics laboratories across the United States that provide clinical testing services specializing in toxicology testing for pain management clinics, drug and alcohol rehabilitation facilities and neurotransmitter testing. It offers its customers a complete, turnkey software product including: a proprietary laboratory ordering and reporting application, an advanced laboratory information management system, electronic health records, and an industry-leading platform for interpreting and reporting complex test results to physicians. Rennova's software is differentiated from that of its competitors by the breadth of its services, each of which is branded separately and is made available to physician groups in whole or in part. The software permits efficient and easy ordering and reporting, electronic health records integration, medical billing services and compliance, and diagnostic interpretation. For more information see www.rennovahealth.com.